Kintor Pharmaceutical Limited (HKG:9939)
2.730
0.00 (0.00%)
Apr 17, 2026, 4:08 PM HKT
Kintor Pharmaceutical Employees
Kintor Pharmaceutical had 123 employees as of December 31, 2025. The number of employees decreased by 45 or -26.79% compared to the previous year.
Employees
123
Change
-45
Growth
-26.79%
Revenue / Employee
295.68K HKD
Profits / Employee
-1.81M HKD
Market Cap
1.35B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 123 | -45 | -26.79% |
| Jun 30, 2025 | 136 | - | - |
| Dec 31, 2024 | 168 | -57 | -25.33% |
| Dec 31, 2023 | 225 | -76 | -25.25% |
| Dec 31, 2022 | 301 | -15 | -4.75% |
| Dec 31, 2021 | 316 | 114 | 56.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1,794 |
| Frontage Holdings | 1,523 |
| Mabpharm | 389 |
| Cutia Therapeutics | 304 |
| Zhaoke Ophthalmology | 276 |
| Transcenta Holding | 171 |
| Beijing Biostar Pharmaceuticals | 131 |
| Brii Biosciences | 75 |
Kintor Pharmaceutical News
- 2 years ago - Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China - PRNewsWire
- 2 years ago - Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China - PRNewsWire
- 2 years ago - Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA - PRNewsWire
- 3 years ago - Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US - PRNewsWire
- 3 years ago - Kintor Pharma Announces 2022 Annual Results and Recent Business Progress - PRNewsWire
- 3 years ago - Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China - PRNewsWire
- 3 years ago - Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023 - PRNewsWire
- 3 years ago - Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound - PRNewsWire